Related references
Note: Only part of the references are listed.The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer
Afsane Bahrami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy
Afsane Bahrami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer
Afsane Bahrami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Role of Wnt/-catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer
Farzad Rahmani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer
Satoshi Okazaki et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives
Mina Hosseini et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2017)
Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
Jin Hai Zheng et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Divergent expression of bacterial wall sensing toll-like receptors 2 and 4 in colorectal cancer
Karoliina Paarnio et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer
Radhashree Maitra et al.
ONCOTARGET (2017)
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
V. Hirsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Current Status and Perspectives Regarding the Therapeutic Potential of Targeting EGFR Pathway by Curcumin in Lung Cancer
Mojtaba Shafiee et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Homeostasis-altering molecular processes as mechanisms of inflammasome activation
Adrian Liston et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model
Tiangeng Dong et al.
BIOCHEMICAL JOURNAL (2016)
Early detection of colorectal cancer: from conventional methods to novel biomarkers
Nasimeh Vatandoost et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer
Lin Xie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer
Lin Xie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Structural Change in Microbiota by a Probiotic Cocktail Enhances the Gut Barrier and Reduces Cancer via TLR2 Signaling in a Rat Model of Colon Cancer
Eugene Dogkotenge Kuugbee et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Application potential of toll-like receptors in cancer immunotherapy: Systematic review
Ming Shi et al.
MEDICINE (2016)
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells
Shu Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Integration of Innate Immune Signaling
Christoph A. Thaiss et al.
TRENDS IN IMMUNOLOGY (2016)
Lipopolysaccharide-induced α-catenin downregulation enhances the motility of human colorectal cancer cells in an NF-κB signaling-dependent manner
Guoping Cheng et al.
ONCOTARGETS AND THERAPY (2016)
Worldwide burden of colorectal cancer: a review
Pasqualino Favoriti et al.
UPDATES IN SURGERY (2016)
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
Martin R. Weihrauch et al.
EUROPEAN JOURNAL OF CANCER (2015)
Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model
Hiroyasu Ito et al.
IMMUNOLOGY (2015)
Toll-like receptor signalling through macromolecular protein complexes
Clare E. Bryant et al.
MOLECULAR IMMUNOLOGY (2015)
Cancer Treatment and Survivorship Statistics, 2014
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells
Hongliang Fang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2014)
Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Abolfazl Avan et al.
CURRENT DRUG TARGETS (2014)
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models
Amy L. Adlard et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
Hans-Joachim Schmoll et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist
Miguel R. Ferreira et al.
LANCET ONCOLOGY (2014)
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib
A. Ray et al.
LEUKEMIA (2014)
The Yin and Yang of Toll-like receptors in cancer
J-P Pradere et al.
ONCOGENE (2014)
Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy
Ting-Ting Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Graphene Oxide Triggers Toll-Like Receptors/Autophagy Responses In Vitro and Inhibits Tumor Growth In Vivo
Guan-Yu Chen et al.
ADVANCED HEALTHCARE MATERIALS (2014)
Toll-like receptor signaling pathways
Takumi Kawasaki et al.
FRONTIERS IN IMMUNOLOGY (2014)
Toll-like receptors and prostate cancer
Shu Zhao et al.
FRONTIERS IN IMMUNOLOGY (2014)
Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors
Nicolas Isambert et al.
BMC CANCER (2013)
Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment-Poor Prognosis or New Therapeutic Opportunity
Lisa A. Ridnour et al.
CLINICAL CANCER RESEARCH (2013)
Functional polymorphisms of Toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans
Pedro Pimentel-Nunes et al.
DIGESTIVE AND LIVER DISEASE (2013)
Toll-like Receptor-4 Expression by Stromal Fibroblasts Is Associated With Poor Prognosis in Colorectal Cancer
Noemi Eiro et al.
JOURNAL OF IMMUNOTHERAPY (2013)
TLR agonists: our best frenemy in cancer immunotherapy
Sabina Kaczanowska et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway
Kurt Lucas et al.
MOLECULAR NEUROBIOLOGY (2013)
TLR2 and TLR4 in the Brain Injury Caused by Cerebral Ischemia and Reperfusion
Ying Wang et al.
MEDIATORS OF INFLAMMATION (2013)
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)
Vincenzo Formica et al.
MEDICAL ONCOLOGY (2013)
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist
Lyudmila G. Burdelya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer
Yasuhiro Nihon-Yanagi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8
Y. Estornes et al.
CELL DEATH AND DIFFERENTIATION (2012)
New developments in Toll-like receptor targeted therapeutics
Dympna J. Connolly et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Toll-like receptor genes and their association with colon and rectal cancer development and prognosis
Martha L. Slattery et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Study of the Expression of Toll-Like Receptors in Different Histological Types of Colorectal Polyps and Their Relationship with Colorectal Cancer
Noemi Eiro et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
CpG ODN, Toll Like Receptor (TLR)-9 Agonist, Inhibits Metastatic Colon Adenocarcinoma in a Murine Hepatic Tumor Model
Ik Yong Kim et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Modulating immunity as a therapy for bacterial infections
Robert E. W. Hancock et al.
NATURE REVIEWS MICROBIOLOGY (2012)
TLR-4 Signalling Accelerates Colon Cancer Cell Adhesion via NF-κB Mediated Transcriptional Up-Regulation of Nox-1
D. Peter O'Leary et al.
PLOS ONE (2012)
Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells
Ce Wang et al.
VACCINE (2012)
Trial Watch Experimental Toll-like receptor agonists for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Targeting the immune system to fight cancer using chemical receptor homing vectors carrying polyinosine/cytosine (PolyIC)
Alexander Levitzki
FRONTIERS IN ONCOLOGY (2012)
Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses
Meghan B. Davis et al.
CLINICAL CANCER RESEARCH (2011)
The Structural Biology of Toll-like Receptors
Istvan Botos et al.
STRUCTURE (2011)
Expression and Functional Research of TLR4 in Human Colon Carcinoma
Xiao-Yan Tang et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2010)
Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy
Jae-Min Yuk et al.
AUTOPHAGY (2010)
High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer
E. L. Wang et al.
BRITISH JOURNAL OF CANCER (2010)
Potentiation of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide
Calin D. Dumitru et al.
CANCER BIOLOGY & THERAPY (2010)
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis
Manabu Taura et al.
CANCER SCIENCE (2010)
Control of infection by pyroptosis and autophagy: role of TLR and NLR
Karina R. Bortoluci et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
TIR-containing adaptors in Toll-like receptor signalling
Kristie A. Jenkins et al.
CYTOKINE (2010)
Toll-like Receptors in Inflammatory Bowel Diseases: A Decade Later
Elke Cario
INFLAMMATORY BOWEL DISEASES (2010)
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18
Rosalba Salcedo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker
Rosaria Cammarota et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Toll-Like Receptor 2 Signaling Protects Mice from Tumor Development in a Mouse Model of Colitis-Induced Cancer
Emily L. Lowe et al.
PLOS ONE (2010)
Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function
Maria T. Abreu
NATURE REVIEWS IMMUNOLOGY (2010)
Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer
I. Niedzielska et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
How Location Governs Toll-Like Receptor Signaling
Akanksha Chaturvedi et al.
TRAFFIC (2009)
Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer
B. Jasani et al.
VACCINE (2009)
An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma
Reinhard Dummer et al.
CLINICAL CANCER RESEARCH (2008)
Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer
Sang Hoon Rhee et al.
GASTROENTEROLOGY (2008)
Structural basis of toll-like receptor 3 signaling with double-stranded RNA
Lin Liu et al.
SCIENCE (2008)
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A : U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up
H. -C. Jeung et al.
ANNALS OF ONCOLOGY (2008)
CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy
Yanal M. Murad et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Holger Kanzler et al.
NATURE MEDICINE (2007)
Innate immunity: structure and function of TLRs
Yves Delneste et al.
M S-MEDECINE SCIENCES (2007)
Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits
CA Uyl-de Groot et al.
VACCINE (2005)
Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Fp-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor
J Neidhart et al.
VACCINE (2004)
Toll-like receptors in the pathogenesis of human disease
DN Cook et al.
NATURE IMMUNOLOGY (2004)
Deficient host-bacteria interactions in inflammatory bowel disease?: The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis
D Franchimont et al.
GUT (2004)
Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease
E Cario et al.
INFECTION AND IMMUNITY (2000)
Share Paper
